**Background of CA4 Antibody**
Carbonic anhydrase IV (CA4), a member of the carbonic anhydrase (CA) enzyme family, is a glycosylphosphatidylinositol (GPI)-anchored protein primarily expressed in renal tissues, vascular endothelia, and the retina. It catalyzes the reversible hydration of carbon dioxide (CO₂) to bicarbonate (HCO₃⁻) and protons (H⁺), playing critical roles in pH regulation, ion transport, and fluid balance. Unlike cytosolic isoforms (e.g., CA2), CA4 is membrane-bound, facilitating its involvement in extracellular processes such as renal acid secretion and retinal function.
CA4 antibodies are immunological tools targeting this isoform, widely used in research to study its expression, localization, and function. Dysregulation of CA4 has been linked to pathologies, including renal tubular acidosis, age-related macular degeneration (AMD), and certain cancers. In cancer biology, CA4 is implicated in tumor microenvironment modulation, where its activity may influence angiogenesis and metastatic progression. Antibodies against CA4 enable detection via techniques like immunohistochemistry, Western blotting, and ELISA, aiding in biomarker discovery and mechanistic studies.
Recent studies also explore CA4 as a therapeutic target. Inhibitors of CA4. combined with antibody-based strategies, are being investigated for diseases like AMD and solid tumors. However, CA4's dual roles in homeostasis and pathology necessitate context-specific research. CA4 antibodies thus serve as essential reagents for unraveling its physiological and pathological contributions, bridging gaps between basic science and clinical applications.